



COPY OF PAPERS  
ORIGINALLY FILED

GP/1647.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants: M. Rigdon Lentz

MAR - 4 2002

Serial No.: 09/709,045

Art Unit: 1647

TECH CENTER 1600/2900

Filed: November 10, 2000

Examiner: Not Yet Assigned

For: *METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS*

#7  
LQJ  
3/25/02

Assistant Commissioner for Patents  
Washington, D.C. 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of the documents cited therein.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 50-1868.

**Foreign Documents**

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 99/61085 A	12-02-1999	Lentz	PCT

**Publications**

GATANAGA, et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients," *Proceedings of the National Academy of the USA* 87(22):8781-87814 (1990).

U.S.S.N.: 09/709,045  
Filed: November 10, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

LENTZ, "Continuous whole blood UltraPheresis procedure in patients with metastatic cancer," *Journal of Biological Response Modifiers* 8(5):511-527 (1989).

LENTZ, "The role of therapeutic apheresis in the treatment of cancer: a review," *Therapeutic Apheresis* 3(1):40-49 (1999).

SELINSKY, et al., "Multifaceted inhibition of anti-tumor immune mechanisms by soluble tumour necrosis factor receptor type-1," *Immunology* 94(1):88-93 (1998).

TETTA, et al., "Continuous plasma filtration coupled with sorbents," *Kidney International* 53(66):S186-S189 (1998).

### Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst  
Reg. No. 31,284

Dated: January 30, 2002


HOLLAND & KNIGHT LLP  
One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400  
404-817-8500  
FAX 404-817-0470  
www.hklaw.com

U.S.S.N.: 09/709,045  
Filed: November 10, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

**Certificate of Mailing under 37 CFR §1.8(a)**

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: January 30, 2002

  
Kimberly L. Adams

ATL1 #505347 v1